Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
Primary resultResult — go to the resultHazard ratio 1.02 95% CI 0.92–1.13Authors' conclusion
In patients with symptomatic peripheral artery disease, ticagrelor was not shown to be superior to clopidogrel for the reduction of cardiovascular events. Major bleeding occurred at similar rates among the patients in the two trial groups.
Study context
- Population
- Symptomatic PAD (ankle-brachial index (ABI) ≤0.80 or previous lower-limb revascularization)
- Participants
- 13,885 participants
- Comparison
- Ticagrelor vs clopidogrel monotherapy
- Ticagrelorn = 6,930
- Clopidogreln = 6,955reference
- Primary endpoint
- Composite of:
- Adjudicated CV death
- MI
- Ischemic stroke
- Follow-up
- Median 30 months
Methodological detailsdouble-blind, event-driven
- Double-blind
- Event-driven
Primary result
As reported in the abstract
Hazard ratio
1.02
95% CI 0.92–1.13
P = 0.65
Events by treatment group
Ticagrelor vs Clopidogrel
HR 1.02 (95% CI 0.92–1.13); P = 0.65
Further findings
| Outcome | Ticagrelor | Clopidogrel | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Acute limb ischemia | 1.7% | 1.7% | 1.03 (0.79–1.33) | P = 0.85 | |
| 0.512Hazard ratio (log scale) |
Safety
| Outcome | Ticagrelor | Clopidogrel | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Major bleeding (primary safety end point) | 1.6% | 1.6% | 1.10 (0.84–1.43) | P = 0.49 | |
| 0.512Hazard ratio (log scale) |
Original publication
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med. Published 13 November 2016. doi:10.
Summarised from the published abstract; every number is checked against it